Buserelin

Buserelin, sold under the brand name Suprefact among others, is a medication which is used primarily in the treatment of prostate cancer and endometriosis.[3][1][2] It is also used for other indications such as the treatment of premenopausal breast cancer, uterine fibroids, and early puberty, in assisted reproduction for female infertility, and as a part of transgender hormone therapy.[6][3][7] In addition, buserelin is used in veterinary medicine.[8] The medication is typically used as a nasal spray three times per day, but is also available for use as a solution or implant for injection into fat.[1][2]

Buserelin
Clinical data
Trade namesSuprefact, others
Other namesEtilamide; HOE-766; HOE-766A; ICI-123215; S-746766; D-Ser(tBu)6EA10-LHRH; 6-[O-(1,1-Dimethylethyl)-D-serine]-9-(N-ethyl-L-prolinamide)-10-deglycinamide-LHRH (pig)
AHFS/Drugs.comMicromedex Detailed Consumer Information
Pregnancy
category
  • X
Routes of
administration		Nasal spray, subcutaneous injection, subcutaneous implant[1][2]
Drug classGnRH analogue; GnRH agonist; Antigonadotropin
ATC code
Legal status
Legal status
  • In general: ℞ (Prescription only)
Pharmacokinetic data
BioavailabilityOral: ineffective[1]
Intranasal: 2.5–3.3%[3]
Subcutaneous: 70%[1]
Protein binding15%[1]
MetabolismLiver, kidneys, gastrointestinal tract (pyroglutamyl peptidase, chymotrypsin-like endopeptidase)[1]
MetabolitesBuserelin (1–5)[4]
Elimination half-lifeIntravenous: 50–80 min[5]
Subcutaneous: 80 min[5]
Intranasal: 1–2 hours[5]
ExcretionUrine, bile[3][5]
Identifiers
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
ChEBI
ChEMBL
ECHA InfoCard100.055.493
Chemical and physical data
FormulaC60H86N16O13
Molar mass1239.447 g·mol−1
3D model (JSmol)
  (verify)

Side effects of buserelin are related to sex hormone deprivation and include symptoms of low testosterone levels and low estrogen levels such as hot flashes, sexual dysfunction, vaginal atrophy, and osteoporosis.[3][1] Buserelin is a gonadotropin-releasing hormone agonist (GnRH agonist) and works by preventing the production of sex hormones by the gonads.[3][1] It can lower sex hormone levels by about 95% in both sexes.[9][10][11] Buserelin is a peptide and an analogue of GnRH.[12]

Buserelin was first patented in 1974 and approved for medical use in 1985.[13] It is not available in the United States, but is marketed widely elsewhere in the world, including in the United Kingdom, Canada, and many other countries.[14][8][15] The medication is one of only two medically used GnRH analogues that are available as nasal sprays, the other being nafarelin.[16] Buserelin is available as a generic medication.[17][18]

Medical uses

Buserelin is approved for the treatment of hormone-responsive cancers including prostate cancer and premenopausal breast cancer, sex hormone-dependent uterine diseases including endometrial hyperplasia, endometriosis, and uterine fibroids, and in assisted reproduction for female infertility.[6][3] It is also used off-label for the treatment of precocious puberty, as a puberty blocker in transgender children, and as a component of transgender hormone therapy.[3][7] In ovulation induction, buserelin is used for pituitary suppression as an adjunct to gonadotropin administration.[19] It has also been assessed as a nasal spray for use as a hormonal contraceptive in women, with a 96% anovulation rate.[3]

Dosages

For prostate cancer, the dosage of buserelin by subcutaneous injection is 500 μg three times per day (once every 8 hours, 1,500 μg/day total) for one week and then 200 μg once daily thereafter.[20][21] If buserelin is used as a nasal spray, the dosage for prostate cancer is 800 μg sprayed into the nostrils three times per day (once every 8 hours, 2,400 μg/day total) for one week followed by 400 μg sprayed into the nostrils three times per day (once every 8 hours, 1,200 μg/day total) thereafter.[21][20] For endometriosis, buserelin is used specifically as a nasal spray and the dosage is the same as that used for prostate cancer.[20] These dosages of buserelin for both subcutaneous injection and nasal spray have been found to decrease testosterone levels to near-castrate levels in men with prostate cancer, although suppression was more complete with subcutaneous injection presumably due to suboptimal absorption with intranasal administration.[22]

Available forms

Buserelin is available in the form of a 1 mg/mL solution for use as a nasal spray or subcutaneous injection once every 8 hours (three times per day) and as 6.3 mg and 9.45 mg implants for subcutaneous injection once every two and three months, respectively.[1][2][23][24]

Contraindications

Contraindications of buserelin include the following:[1][2]

Side effects

During the initial phase of the therapy, before GnRH receptors have been significantly downregulated, testosterone levels are increased.[3][1] This can lead to transient tumor activation with bone pain (in patients with cancer metastases) and urinary retention.[3][1] Side effects that occur later during the treatment are mainly due to low sex hormone levels and include reduced libido, erectile dysfunction, hot flashes, vaginal dryness, vaginal atrophy, menorrhagia, osteoporosis, depression, asthenia, emotional lability, headache, dizziness, and application site reactions.[3][1]

Overdose

Buserelin appears to be safe in the event of an overdose.[1][2]

Pharmacology

Pharmacodynamics

Buserelin is a GnRH agonist, or an agonist of the GnRH receptor.[3][1] It is a superagonist of the GnRH receptor with potency for induction of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) secretion of about 20 to 170 times that of GnRH itself.[3][1] By activating the GnRH receptor in the pituitary gland, buserelin induces the secretion of LH and FSH from the gonadotrophs of the anterior pituitary, which travel to the gonads through the bloodstream and activate gonadal sex hormone production as well as stimulate spermatogenesis in men and induce ovulation in women.[3][1]

With chronic administration of buserelin however, the GnRH receptor becomes desensitized and completely stops responding both to buserelin and to endogenous GnRH.[3][1] This is because GnRH is normally released from the hypothalamus in pulses, which keeps the GnRH receptor sensitive, whereas chronic buserelin administration results in more constant exposure and desensitization of the receptor.[3][1] The profound desensitization of the GnRH receptor results in a loss of LH and FSH secretion from the anterior pituitary and a consequent shutdown of gonadal sex hormone production, markedly diminished or abolished spermatogenesis in men, and anovulation in women.[3][1]

In men, approximately 95% of circulating testosterone is produced by the testes, with the remaining 5% being derived from the adrenal glands.[9] In accordance, GnRH analogues like buserelin can reduce testosterone levels by about 95% in men.[9][22] Sex hormone levels, including those of estradiol and progesterone, are similarly profoundly suppressed in premenopausal women.[10] The suppression of estradiol levels is 95% and progesterone levels are less than 1 ng/mL (normal range during the luteal phase approximately 10–20 ng/mL); the resulting levels are equivalent to those in postmenopausal women.[10][11]

Buserelin has been found to suppress testosterone levels in men with prostate cancer from 426 ng/dL to 28 ng/dL (by 93.4%) with 200 μg by subcutaneous injection once per day and from 521 ng/dL to 53 ng/dL (by 89.8%) with 400 μg by nasal spray once every 8 hours (1,200 μg/day total).[25] The difference in suppression may have been due to poor compliance.[25] A few small studies have also assessed the suppression of testosterone levels with buserelin nasal spray twice a day instead of three times a day.[26][27] One such study found that testosterone levels in men with prostate cancer were suppressed during treatment with buserelin from 332 ng/dL to 215 ng/dL (28.9% lower than controls) with 200 μg by nasal spray twice a day (400 μg/day total), from 840 ng/dL to 182 ng/dL (71.4% lower than controls) with 500 μg by nasal spray twice a day (1,000 μg/day total), and from 598 ng/dL to 126 ng/dL (80.4% lower than controls) with 50 μg by subcutaneous injection once a day.[26]

Pharmacokinetics

Buserelin is ineffective via oral administration due to first-pass metabolism in the gastrointestinal tract.[1] Its bioavailability is 2.5 to 3.3% by intranasal administration and 70% by subcutaneous injection.[1] The plasma protein binding of buserelin is approximately 15%.[1] The metabolism of buserelin occurs in the liver, kidneys, and gastrointestinal tract and is mediated by peptidases, specifically pyroglutamyl peptidase and chymotrypsin-like endopeptidase.[1] The elimination half-life of buserelin regardless of route of administration is about 72 to 80 minutes.[1] Buserelin and its metabolites are eliminated in urine and bile, with approximately 50% of buserelin excreted in urine unchanged.[1][5]

Chemistry

Buserelin is a GnRH analogue, or a synthetic analogue of GnRH.[3][1] It is a nonapeptide and is also known as [D-Ser(tBu)6,des-Gly-NH210]GnRH ethylamide or as D-Ser(tBu)6EA10-GnRH.[3][1][28] Buserelin is marketed for medical use in both its free base (buserelin) and acetate salt (buserelin acetate) forms.[8]

History

Buserelin was first described in 1976 and was introduced for medical use in 1984.[29][30] Intranasal buserelin was the first GnRH agonist demonstrated to achieve medical castration in humans.[31] This was initially observed via a marked decrease in circulating testosterone levels in a single patient in 1980.[31]

Society and culture

Generic names

Buserelin is the generic name of the drug and its INN and BAN, while buserelin acetate is its USAN, BANM, and JAN, buséréline is its DCF, and buserelina is its DCIT.[32][8][33][14] While under development by Hoechst AG, buserelin was also known as HOE-766.[32][8][33][14]

Brand names

Buserelin is marketed by Sanofi-Aventis primarily under the brand names Suprefact, Suprefact Depot, and Suprecur.[8][14] It is also available under a number of other brand names including Bigonist, Bucel, Buserecur, Fuset, Metrelef, Profact, Profact Depot, Supremon, and Zerelin.[8][14] CinnaFact is a generic version of the medication that is produced by CinnaGen.[18] Buserelin is marketed for use in veterinary medicine primarily under the brand name Receptal, but is also available under the brand names Buserol, Busol, Porceptal, and Veterelin.[8][14]

Availability

Buserelin is marketed in the United Kingdom, Ireland, other European countries, Canada, New Zealand, and South Africa, as well as in Latin America, Asia, and elsewhere in the world.[8][14][15] It is not available in the United States or Australia.[8][14][34]

Research

The steroidal antiandrogen cyproterone acetate has been studied for blocking the testosterone flare at the start of buserelin therapy in men with prostate cancer.[35][36] While cyproterone acetate for two weeks eliminates the biological and biochemical signs of the flare, no benefits on prostate cancer outcomes were observed.[35]

See also

References
  1. http://products.sanofi.ca/en/suprefact.pdf
  2. http://products.sanofi.ca/en/suprefact-depot.pdf
  3. Brogden RN, Buckley MM, Ward A (1990). "Buserelin. A review of its pharmacodynamic and pharmacokinetic properties, and clinical profile". Drugs. 39 (3): 399–437. doi:10.2165/00003495-199039030-00007. PMID 2109679.
  4. K. Höffken (6 December 2012). Peptides in Oncology I: LH-RH Agonists and Antagonists. Springer Science & Business Media. pp. 77–. ISBN 978-88-470-2186-0.
  5. https://www.drugbank.ca/drugs/DB06719
  6. http://adisinsight.springer.com/drugs/800043601
  7. Wilczynski C, Emanuele MA (2014). "Treating a transgender patient: overview of the guidelines". Postgrad Med. 126 (7): 121–8. doi:10.3810/pgm.2014.11.2840. PMID 25387220. S2CID 22639336.
  8. Index Nominum 2000: International Drug Directory. Taylor & Francis. 2000. pp. 149–. ISBN 978-3-88763-075-1.
  9. R.A.S. Hemat (2 March 2003). Andropathy. Urotext. pp. 120–. ISBN 978-1-903737-08-8.
  10. Kenneth L. Becker (2001). Principles and Practice of Endocrinology and Metabolism. Lippincott Williams & Wilkins. pp. 973–. ISBN 978-0-7817-1750-2.
  11. S.L. Corson; R.J. Derman (15 December 1995). Fertility Control. CRC Press. pp. 249–250. ISBN 978-0-9697978-0-7.
  12. Ved Srivastava (26 June 2017). Peptide-based Drug Discovery: Challenges and New Therapeutics. Royal Society of Chemistry. pp. 182–. ISBN 978-1-78262-732-6.
  13. Fischer, Jnos; Ganellin, C. Robin (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 514. ISBN 9783527607495.
  14. https://www.drugs.com/international/buserelin.html
  15. https://health-products.canada.ca/dpd-bdpp/
  16. T. Metin Önerci (17 August 2013). Nasal Physiology and Pathophysiology of Nasal Disorders. Springer Science & Business Media. pp. 208–. ISBN 978-3-642-37250-6.
  17. E Farkas; M Ryadnov (31 August 2013). Amino Acids, Peptide and Proteins. Royal Society of Chemistry. pp. 227–. ISBN 978-1-84973-585-8.
  18. https://www.cinnagen.com/Product.aspx?t=2&l=1&Id=59&f=3
  19. Siristatidis CS, Gibreel A, Basios G, Maheshwari A, Bhattacharya S (2015). "Gonadotrophin-releasing hormone agonist protocols for pituitary suppression in assisted reproduction" (PDF). Cochrane Database Syst Rev (11): CD006919. doi:10.1002/14651858.CD006919.pub4. hdl:2164/7687. PMID 26558801.
  20. http://www.medbroadcast.com/drug/getdrug/suprefact
  21. John E. Niederhuber; James O. Armitage; James H. Doroshow; Michael B. Kastan, Joel E. Tepper (12 September 2013). Abeloff's Clinical Oncology E-Book. Elsevier Health Sciences. pp. 446–. ISBN 978-1-4557-2881-7.
  22. Rajfer J, Handelsman DJ, Crum A, Steiner B, Peterson M, Swerdloff RS (1986). "Comparison of the efficacy of subcutaneous and nasal spray buserelin treatment in suppression of testicular steroidogenesis in men with prostate cancer". Fertil. Steril. 46 (1): 104–10. doi:10.1016/s0015-0282(16)49466-5. PMID 3087785.
  23. Kanthi Bansal (30 May 2013). Manual of Endometriosis. JP Medical Ltd. pp. 99–. ISBN 978-93-5090-404-6.
  24. Alistair Howard Gray; Jane Wright; Vincent Goodey; Lynn Bruce (June 2010). Injectable Drugs Guide. Pharmaceutical Press. pp. 98–. ISBN 978-0-85369-787-9.
  25. Soloway MS (1988). "Efficacy of buserelin in advanced prostate cancer and comparison with historical controls". Am. J. Clin. Oncol. 11 Suppl 1: S29–32. doi:10.1097/00000421-198812001-00006. PMID 3133944. S2CID 10101250.
  26. Faure N, Labrie F, Lemay A, Bélanger A, Gourdeau Y, Laroche B, Robert G (March 1982). "Inhibition of serum androgen levels by chronic intranasal and subcutaneous administration of a potent luteinizing hormone-releasing hormone (LH-RH) agonist in adult men". Fertil. Steril. 37 (3): 416–24. doi:10.1016/S0015-0282(16)46107-8. PMID 6800852.
  27. Tolis G, Faure N, Koutsilieris M, Lemay A, Klioze S, Yakabow A, Fazekas AT (July 1983). "Suppression of testicular steroidogenesis by the GnRH agonistic analogue Buserelin (HOE-766) in patients with prostatic cancer: studies in relation to dose and route of administration". J. Steroid Biochem. 19 (1C): 995–8. doi:10.1016/0022-4731(83)90045-6. PMID 6411994.
  28. Tommaso Falcone; William W. Hurd (14 June 2017). Clinical Reproductive Medicine and Surgery: A Practical Guide. Springer. pp. 9–. ISBN 978-3-319-52210-4.
  29. Kuhl, H.; Kaplan, H.-G.; Taubert, H.-D. (1976). "Effects of a new analogue of LH-RH, D-Ser(TBU)6-EA10-LH-RH, on gonadotropin liberation in males". Deutsche Medizinische Wochenschrift. 101 (10): 361–364. doi:10.1055/s-0028-1104089. ISSN 0012-0472. PMID 129323.
  30. Annual Reports in Medicinal Chemistry. Academic Press. 8 September 1989. pp. 351–. ISBN 978-0-08-058368-6.
  31. Labrie F (August 2014). "GnRH agonists and the rapidly increasing use of combined androgen blockade in prostate cancer". Endocr. Relat. Cancer. 21 (4): R301–17. doi:10.1530/ERC-13-0165. PMID 24825748.
  32. J. Elks (14 November 2014). The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer. pp. 192–. ISBN 978-1-4757-2085-3.
  33. I.K. Morton; Judith M. Hall (6 December 2012). Concise Dictionary of Pharmacological Agents: Properties and Synonyms. Springer Science & Business Media. pp. 57–. ISBN 978-94-011-4439-1.
  34. "Drugs@FDA: FDA Approved Drug Products". United States Food and Drug Administration. Retrieved 17 December 2017.
  35. Louis J Denis; Keith Griffiths; Amir V Kaisary; Gerald P Murphy (1 March 1999). Textbook of Prostate Cancer: Pathology, Diagnosis and Treatment: Pathology, Diagnosis and Treatment. CRC Press. pp. 308–. ISBN 978-1-85317-422-3.
  36. Klosterhalfen, H.; Jacobi, G. H. (1988). "Long-term results of an LH-RH agonist monotherapy in patients with carcinoma of the prostate and reflections on the so-called total androgen blockade with pre-medicated cyproterone acetate": 127–137. doi:10.1515/9783110853674-014. Cite journal requires |journal= (help)

Further reading
  • Roila F (1989). "Buserelin in the treatment of prostatic cancer". Biomed. Pharmacother. 43 (4): 279–85. doi:10.1016/0753-3322(89)90009-7. PMID 2506941.
  • Trabant H, Widdra W, de Looze S (1990). "Efficacy and safety of intranasal buserelin acetate in the treatment of endometriosis: a review of six clinical trials and comparison with danazol". Prog. Clin. Biol. Res. 323: 357–82. PMID 2106146.
  • Brogden RN, Buckley MM, Ward A (1990). "Buserelin. A review of its pharmacodynamic and pharmacokinetic properties, and clinical profile". Drugs. 39 (3): 399–437. doi:10.2165/00003495-199039030-00007. PMID 2109679.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.